Benefits of Nd:YAG 1064 nm laser in the treatment of the face and lower limb telangiectasia

Determining the benefits and side effects of the Nd:YAG 1064 nm laser in order to achieve an effective pulse width with minimal side effects in the treatment of the face and lower limb telangiectasia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100314003566N13

Enrollment

Registered

2023-12-02

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Facial telangiectasia. Condition 2: Lower limb telangiectasia. Hereditary hemorrhagic telangiectasia Hereditary hemorrhagic telangiectasia

Interventions

Intervention 1: Intervention group 1: Patients with facial telangiectasia treated with alexandrite laser with a wavelength of 1064 nm (Alexandrite ND: YAG, CA, USA) with fluence parameters of 140 and

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with facial telangiectasia Patients with telangiectasia of lower limbs Consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Patients with a history of coagulation disorders Suffering from chronic systemic liver diseases Patients with a history of hypertrophic scars and prone to keloid

Design outcomes

Primary

Measure	Time frame
Recovery rate of telangiectasia. Timepoint: Patients will be examined at baseline, 4 weeks after the first treatment, 4 weeks after the second treatment, and 4 weeks after the last evaluation. Method of measurement: Dermoscopy imaging.;Patient satisfaction. Timepoint: Patients will be examined at baseline, 4 weeks after the first treatment, 4 weeks after the second treatment, and 4 weeks after the last evaluation. Method of measurement: Interview with patients.;Side effects. Timepoint: Patients will be examined at baseline, 4 weeks after the first treatment, 4 weeks after the second treatment, and 4 weeks after the last evaluation. Method of measurement: Including wounds, scars, erythema, hyperpigmentation, hypopigmentation and blisters, which will be evaluated by a clinical examination by a dermatologist.	—

Measure

Time frame

Recovery rate of telangiectasia. Timepoint: Patients will be examined at baseline, 4 weeks after the first treatment, 4 weeks after the second treatment, and 4 weeks after the last evaluation. Method of measurement: Dermoscopy imaging.;Patient satisfaction. Timepoint: Patients will be examined at baseline, 4 weeks after the first treatment, 4 weeks after the second treatment, and 4 weeks after the last evaluation. Method of measurement: Interview with patients.;Side effects. Timepoint: Patients will be examined at baseline, 4 weeks after the first treatment, 4 weeks after the second treatment, and 4 weeks after the last evaluation. Method of measurement: Including wounds, scars, erythema, hyperpigmentation, hypopigmentation and blisters, which will be evaluated by a clinical examination by a dermatologist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hamide Azimi

Tabriz University of Medical Sciences

azimi@tbzmed.ac.ir+98 41 1540 6612

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026